The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.
about
AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical TrialsAdaptive dose-finding studies: a review of model-guided phase I clinical trials.Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administrationAdaptive designs for dual-agent phase I dose-escalation studies.Embracing model-based designs for dose-finding trials.Incorporating adverse event relatedness into dose-finding clinical trial designs.Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
P2860
Q28552571-48739B58-A1AB-4B8B-A8E0-E416D479C79AQ34001009-FD100749-FA61-48E7-9555-A8743FF79904Q36761020-3FF5DB5A-2500-4C23-B62E-1D9CA4824431Q37505622-28766E7F-E106-4899-BF7B-C90AE1839871Q38090897-153EE239-D8CF-4162-B564-EE3C279B76C5Q38700689-6FA4725D-E919-4601-B661-E5E89E7D9F76Q43681160-20363FC2-36C5-4B25-A0B2-B8DB050FBB57Q47223679-8A527140-1F0C-47B8-9610-806ECDD7C98CQ47626358-00C79A97-837A-41EE-B116-1DE60A306AD6Q58800877-9A03A573-B714-4354-A2B6-59B5BFC216CF
P2860
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The impact of non-drug-related ...... erated dose in phase I trials.
@ast
The impact of non-drug-related ...... erated dose in phase I trials.
@en
type
label
The impact of non-drug-related ...... erated dose in phase I trials.
@ast
The impact of non-drug-related ...... erated dose in phase I trials.
@en
prefLabel
The impact of non-drug-related ...... erated dose in phase I trials.
@ast
The impact of non-drug-related ...... erated dose in phase I trials.
@en
P2093
P2860
P1476
The impact of non-drug-related ...... erated dose in phase I trials.
@en
P2093
Alexia Iasonos
David M Hyman
David R Spriggs
John F Gerecitano
John O'Quigley
Mrinal Gounder
Sarah Zohar
P2860
P304
P356
10.1158/1078-0432.CCR-12-0726
P407
P577
2012-07-23T00:00:00Z